Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (NASDAQ:AZN) blockbuster cancer drug Enhertu, developed with Japanese pharmaceutical giant Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY), would be added to state health insurance reimbursement in China, the country’s health officials announced Thursday.
Addition of Enhertu to China’s National Reimbursement Drug List